Glenmark Pharmaceuticals Limited — Important, 24-02-2025: General Updates

Glenmark Pharmaceuticals is involved in ongoing legal proceedings, predominantly related to antitrust and consumer protection lawsuits concerning its generic version of Zetia® and its combination with Vytorin®. The company, along with its subsidiary in the U.S., has faced multiple lawsuits alleging anticompetitive behavior linked to a 2010 settlement with Schering Corporation.

In 2023, Glenmark settled with three plaintiff groups for a total of USD 7 million. Notably, this settlement underscores that Glenmark denies all allegations and does not admit to any liability. However, four plaintiffs opted out of this settlement, and their lawsuits will continue in their respective jurisdictions. As Glenmark navigates these legal challenges, ongoing settlements may alleviate potential financial burdens while allowing the company to maintain its operational focus. Investors should watch closely for further developments in these litigations and their potential impacts on Glenmark’s financial health.